NVO

37.8202.70%
CD

Cornelis de Jong

Independent Vice Chair of the Board

Dr. Cornelis de Jong, also known as Cees, M.D., MBA, is an experienced leader in Biotechnology and Biomanufacturing. He will serve as Independent Vice Chair of the Board of Novo Nordisk A/S from November 14, 2025. He serves as Chairman of the Board at Novonesis A/S since March 2, 2023. Dr. de Jong holds several other chairman and board positions. He serves as Chairman of the Management Board, Managing Director, and Member of the Management Board of Axa Belgium Finance (NL) B.V.; as Chairman of the Supervisory Board at Polyganics B.V. since July 2012 and at GreenChem BV; and as Chair of Oterra Holding ApS, Meatable B.V., Mediq B.V., and A-Mansia Biotech S.A. Additionally, he serves as a Director of Protein Sciences Corporation and as a Member of the Dutch Supervisory Board of Quest International. Previously, Dr. de Jong was a Venture Partner of Forbion Capital Partners B.V. from June 2024. He served as Chairman of the Supervisory Board at ForFarmers N.V. from April 2018 to April 23, 2021, and had been a Member of its Supervisory Board since April 2017. At Novonesis A/S, he also served as Independent Vice Chairman from February 2020 to March 2023. He was the Chief Executive Officer of Chr. Hansen Holding A/S from April 1, 2013 to May 31, 2018, and also served as its President and a Member of the Executive Board. He served as the Chief Operating Officer of Crucell N.V. from September 2007 to 2011 and as a Member of its Management Board from 2008. From 2003 to 2007, he was Group Vice President at ICI and Group Vice President in Charge of the Flavours Division of Quest International, also serving as a Member of the Board at both companies. He was Business Group Director at Campina from 2000 to 2002. His earlier career includes serving as President of DSM Anti-infectives since 1998 and as Business Group Director at Gist-brocades, N.V. from 1989 to 2000, where he started his career and also served as Managing Director for the Industrial Pharmaceutical division. Dr. de Jong holds a Medical Degree from 1987 and an MBA from 1989 from the Erasmus University in Rotterdam.

Positions